Table 2.

HR and 95% CIs for the association between oxidative stress–related genetic variants and advanced prostate cancer risk, Netherlands Cohort Study, 1986–2003a

Advanced (stage III/IV) prostate cancerbStage IV prostate cancerc
SNP rsIDGenotypePerson-yearsNo. of eventsHR (95% CI)PtrenddNo. of eventsHR (95% CI)Ptrendd
CAT rs1001179GG15,7945521.003351.00
AG8,1083281.15 (0.96–1.36)2111.21 (0.99–1.49)
AA1,282601.38 (0.97–1.97)431.64 (1.10–2.44)
Per minor allele25,1849401.16 (1.01–1.33)0.0325891.25 (1.07–1.46)0.006
hOGG1 rs1052133CC15,1705461.003411.00
CG9,1343571.09 (0.92–1.29)2251.10 (0.90–1.34)
GG1,122491.25 (0.85–1.84)291.19 (0.76–1.88)
Per minor allele25,4269521.10 (0.96–1.27)0.1775951.10 (0.93–1.29)0.265
NOS2A rs2297518GG16,6806161.004041.00
AG7,7243111.09 (0.91–1.30)1750.93 (0.76–1.15)
AA1,022250.67 (0.42–1.08)160.66 (0.37–1.15)
Per minor allele25,4269520.99 (0.86–1.13)0.8395950.89 (0.75–1.06)0.179
NOS2A rs9282801GG10,3704071.002661.00
GT11,7684270.94 (0.79–1.12)2540.86 (0.70–1.05)
TT3,2881180.95 (0.73–1.24)750.93 (0.69–1.26)
Per minor allele25,4269520.97 (0.86–1.09)0.5715950.93 (0.81–1.08)0.330
NOS3A rs1799983GG11,8364331.002661.00
GT11,1474181.02 (0.86–1.21)2691.07 (0.88–1.31)
TT2,4261001.13 (0.85–1.49)591.08 (0.77–1.51)
Per minor allele25,4099511.05 (0.92–1.19)0.4685941.05 (0.91–1.22)0.493
NQ1 rs1800566CC17,9016621.004131.00
CT6,7352561.06 (0.88–1.27)1591.06 (0.85–1.31)
TT778341.16 (0.74–1.81)231.25 (0.75–2.07)
Per minor allele25,4139521.07 (0.92–1.24)0.4105951.08 (0.91–1.29)0.389
PON1 rs662AA12,9384811.003131.00
AG10,3123830.98 (0.83–1.16)2290.90 (0.74–1.10)
GG2,176881.08 (0.81–1.44)531.00 (0.71–1.40)
Per minor allele25,4269521.02 (0.90–1.15)0.8155950.96 (0.82–1.11)0.566
PON1 rs854560AA10,2003821.002381.00
AT11,9144440.99 (0.84–1.18)2720.98 (0.80–1.20)
TT3,3121261.00 (0.78–1.30)851.08 (0.81–1.45)
Per minor allele25,4269521.00 (0.89–1.13)0.9915951.02 (0.89–1.18)0.735
SOD1 rs10432782TT19,5957321.004461.00
GT5,3692071.03 (0.84–1.25)1391.13 (0.90–1.42)
GG461130.78 (0.40–1.52)100.99 (0.47–2.09)
Per minor allele25,4269520.99 (0.83–1.17)0.8985951.09 (0.90–1.33)0.376
SOD2 rs4816407AA23,0018481.005261.00
AG + GG2,4091041.16 (0.89–1.51)691.24 (0.91–1.68)
SOD2 rs4880TT6,6742471.001641.00
CT12,6054790.99 (0.82–1.21)2940.91 (0.73–1.15)
CC6,1472260.95 (0.75–1.20)1370.86 (0.66–1.13)
Per minor allele25,4269520.98 (0.87–1.09)0.6665950.93 (0.81–1.06)0.283

Abbreviation: rsID, reference SNP ID number.

  • aAll models were adjusted for age at baseline (y).

  • bAdvanced (International Union Against Cancer, stage III/IV) prostate cancer was stage T3−4, N+, or M1 at diagnosis.

  • cStage IV prostate cancer was stage T4, N+, or M1 at diagnosis.

  • dAnalysis for linear trend according to the number of variant alleles (0, 1, or 2). All statistical tests were two sided.